Adipose tissue-derived stem cells show both immunogenic and immunosuppressive properties after chondrogenic differentiation

References

• Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, . Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143–7.
   PubMed Web of Science ®Google Scholar
• Chamberlain G, Fox J, Ashton B, Middleton J. Concise Review: Mesenchymal stem cells: their phenotype, differentiation capacity immunological features and potential for homing. Stem Cells 2007;25:2739–49.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringdén O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11–20
   PubMed Web of Science ®Google Scholar
• Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, . Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42–8.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105: 1815–22.
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007;110:3499–3506.
   PubMed Web of Science ®Google Scholar
• Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, . Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001;7:211–28.
   PubMedGoogle Scholar
• Yanez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramírez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of graft-versus-host disease. Stem Cells 2006;24:2582–91
   PubMed Web of Science ®Google Scholar
• Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, . Immunomodulatory effect of human adipose tissue derived stem cells: comparison with bone marrow derived stem cells. Br J Hematol 2005;129:118–29.
   PubMed Web of Science ®Google Scholar
• Cui L, Yin S, Liu W, Li N, Zhang W, Cao Y. Expanded adipose-derived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin E. Tissue Eng 2007;13:1185–95.
   PubMedGoogle Scholar
• Auguello A, Tasso R, Negrini SM, Cancedda R, Pennesi G. Cell therapy using allogeneic mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 2007;56:1175–86.
   PubMedGoogle Scholar
• González MA, González-Rey E, Rico L, Büscher D, Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009;60:1006–19.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringdén O. HLA expression of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;31:890–6.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Rasmussen I, Sundberg B, Götherström C, Hassan M, Uzunel M, . Treatment of severe graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439–41.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, . Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371:1579–86.
   PubMed Web of Science ®Google Scholar
• Reddy P, Arora M, Guimond M, Haynesworth SE, Ringdén O. GVHD: A Continuing Barrier to the Safety of Allogeneic Transplantation. Biol Blood Marrow Transplant 2008;15:162–8.
   Web of Science ®Google Scholar
• Lefebvre V, Behringer RR, Crombrugghe C. L-Sox5, Sox6 and Sox9 control essential steps of the Chondrocyte differentiation pathway. Osteoarthr Cartil 2001;9:S69–S75.
   PubMed Web of Science ®Google Scholar
• Lefebvre V, Dumitriu B, Penzo-Mendez A, Han Y, Pallavi B. Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors. Int J Biochem Cell Biol 2007;39:2195–214.
   PubMed Web of Science ®Google Scholar
• Han Y, Lefebvre V. L-Sox5 and Sox6 Drive Expression of the Aggrecan Gene in Cartilage by Securing Binding of Sox9 to a Far-Upstream Enhancer. Mol Cell Biol 2008; 28: 4999–5013.
   PubMed Web of Science ®Google Scholar
• Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, . Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFoxP3+ regulatory T cells. Stem Cells 2008;26:212–22.
   PubMed Web of Science ®Google Scholar
• Selmani Z, Naji A, Gaiffe E, Obert L., Tiberghien P, Rouas-Freiss N, . HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation 2009;87:62–6.
   Web of Science ®Google Scholar
• Meliga E, Strem BM, Duckers HJ, Serruys PW. Adipose-derived cells. Cell Transplant. 2007;16:963–70.
   PubMed Web of Science ®Google Scholar
• Kilroy GE, Foster SJ, Wu X, Ruiz J, Sherwood S, Heifetz A, . Cytokine profile of human adipose-derived stem cells: expression of angiogenic, hematopoietic, and pro-inflammatory factors. J Cell Physiol 2007;212:702–9.
   PubMed Web of Science ®Google Scholar
• Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999;190:995–1004.
   PubMed Web of Science ®Google Scholar
• Stagg J, Pommey S, Eliopoulos N, Galipeau J. Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 2006;107: 2570–7.
   PubMed Web of Science ®Google Scholar
• Chan JL, Tang KC, Patel AP, Pierobon N, Ponzio NM, Rameshwar P. Antigen-presenting property of mesenchymal stem cells occurs during narrow window at low levels of interferon-gamma. Blood 2006;107:4817–24.
   PubMed Web of Science ®Google Scholar
• Langer F, Gross AE. Immunogenicity of Allograft Articular Cartilage. J Bone Joint Surg Am 1974;56:297–304.
   PubMed Web of Science ®Google Scholar
• Niemeyer P, Krause U, Kasten P, Kreuz PC, Henle P, Südkam NP, . Mesenchymal stem cell-based HLA-independent cell therapy for tissue engineering of bone and cartilage. Curr Stem Cell Res Ther 2006;1:21–27.
   PubMedGoogle Scholar
• Robinson D, Guetsky M, Halperin R, Schneider D, Nevo Z. Articular cartilage reconstruction using xenogeneic epiphyses slices. Cell Tissue Bank 2002;3:269–77.
   PubMedGoogle Scholar
• Wang EC, Damrose EJ, Mendelsohn AH, Nelson SD, Shintaku IP, Ye M, . Distribution of class I and II human leukocyte antigens in the larynx. Otolaryngol Head and Neck Surg 2006;134:280–7.
   PubMed Web of Science ®Google Scholar
• Shipchandler T, Lorenz RR, Lee WT, Teker AM, Dan O, Strome M. Laryngeal Transplantation in the Setting of Cancer: A Rat Model. Laryngoscope 2008;118:2166–71.
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in an non-myeloablative setting. Blood 2006;108:2114–20.
   PubMed Web of Science ®Google Scholar
• Rasmusson I, Uhlin M, Le Blanc K, Levitsky V. Mesenchymal stem cells fail to trigger effector functions of cytotoxic T cells. J Leukoc Biol 2007;82:887–93.
   PubMed Web of Science ®Google Scholar